Outcomes in Clinical Trials

Edited by Martin Kolb and Claus F. Vogelmeier
The traditional end-points for clinical studies of lung diseases were based on functional parameters. Their value as surrogate markers for disease activity and progression has been increasingly questioned by scientists, carers, regulatory agencies and funding bodies. Novel tools and methods with regard to biomarkers and patient-reported outcomes have made these parameters emerge from their status as interesting secondary end-points and become potential primary outcomes for clinical trials. Nevertheless, their relevance and validity still needs to be proven. This issue of the European Respiratory Monograph describes the current status regarding end-points in all relevant areas of pulmonary medicine. 

Contents list

Outcomes in clinical trials: specific disease areas
1. Chronic obstructive pulmonary disease
2. Asthma
3. Idiopathic pulmonary fibrosis
4. Cystic fibrosis
5. Pulmonary arterial hypertension
6. The intensive care unit

Outcomes in clinical trials: specific outcomes
7. Biomarkers
8. Health status measurement
9. Electronic patient-reported outcomes
10. Physical activity
11. Lung function
12. Imaging
13. Exercise tests
14. Omics

ISBN: 978-1-84984-044-6